The Effects of IGF-1 on TNF-α-Treated DRG Neurons by Modulating ATF3 and GAP-43 Expression via PI3K/Akt/S6K Signaling Pathway
- 16 February 2017
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 42 (5) , 1403-1421
Abstract
Upregulation of the pro-inflammatory cytokine tumor necrosis factor α (TNF-α) is involved in the development and progression of numerous neurological disorders. Recent reports have challenged the concept that TNF-α exhibits only deleterious effects of pro-inflammatory destruction, and have raised the awareness that it may play a beneficial role in neuronal growth and function in particular conditions, which prompts us to further investigate the role of this cytokine. Insulin-like growth factor-1 (IGF-1) is a cytokine possessing powerful neuroprotective effects in promoting neuronal survival, neuronal differentiation, neurite elongation, and neurite regeneration. The association of IGF-1 with TNF-α and the biological effects, produced by interaction of IGF-1 and TNF-α, on neuronal outgrowth status of primary sensory neurons are still to be clarified. In the present study, using an in vitro model of primary cultured rat dorsal root ganglion (DRG) neurons, we demonstrated that TNF-α challenge at different concentrations elicited diverse biological effects. Higher concentration of TNF-α (10 ng/mL) dampened neurite outgrowth, induced activating transcription factor 3 (ATF3) expression, reduced growth-associated protein 43 (GAP-43) expression, and promoted GAP-43 and ATF3 coexpression, which could be reversed by IGF-1 treatment; while lower concentration of TNF-α (1 ng/mL) promoted neurite sprouting, decreased ATF3 expression, increased GAP-43 expression, and inhibited GAP-43 and ATF3 coexpression, which could be potentiated by IGF-1 supplement. Moreover, IGF-1 administration restored the activation of Akt and p70 S6 kinase (S6K) suppressed by higher concentration of TNF-α (10 ng/mL) challenge. In contrast, lower concentration of TNF-α (1 ng/mL) had no significant effect on Akt or S6K activation, and IGF-1 administration activated these two kinases. The effects of IGF-1 were abrogated by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. These data imply that IGF-1 counteracts the toxic effect of higher concentration of TNF-α, while potentiates the growth-promoting effect of lower concentration of TNF-α, with the node for TNF-α and IGF-1 interaction being the PI3K/Akt/S6K signaling pathway. This study is helpful for interpretation of the association of IGF-1 with TNF-α and the neurobiological effects elicited by interaction of IGF-1 and TNF-α in neurological disorders.Keywords
Funding Information
- National Natural Science Foundation of China (81371929)
- the National Science and Technology Innovation Project for College Students of China (201510422097)
This publication has 44 references indexed in Scilit:
- Atf3 mutant mice show reduced axon regeneration and impaired regeneration-associated gene induction after peripheral nerve injuryOpen Biology, 2016
- The therapeutic potential of insulin-like growth factor-1 in central nervous system disordersNeuroscience & Biobehavioral Reviews, 2016
- Sensory experience regulates cortical inhibition by inducing IGF1 in VIP neuronsNature, 2016
- MASH1/Ascl1a Leads to GAP43 Expression and Axon Regeneration in the Adult CNSPLOS ONE, 2015
- Demyelination and other neurological adverse events after anti-TNF therapyAutoimmunity Reviews, 2014
- SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patientsNature, 2013
- Parkinson disease: from pathology to molecular disease mechanismsFree Radical Biology and Medicine, 2013
- Tumor necrosis factor-α elevates neurite outgrowth through an NF-κB-dependent pathway in cultured adult sensory neurons: Diminished expression in diabetes may contribute to sensory neuropathyBrain Research, 2011
- Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuliPain, 2010
- Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesArthritis & Rheumatism, 2001